Holen Sie sich die Stockscreener-App
1.61
0.63%
0.01
Handel nachbörslich:
1.61
Schlusskurs vom Vortag:
$1.60
Offen:
$1.6
24-Stunden-Volumen:
57,794
Relative Volume:
0.12
Marktkapitalisierung:
$70.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-1.9167
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
+1.26%
1M Leistung:
-13.90%
6M Leistung:
+114.70%
1J Leistung:
+29.84%
1-Tages-Spanne:
$1.59
$1.69
1-Wochen-Bereich:
$1.545
$1.78
52-Wochen-Spanne:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.61 | 70.84M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
Quince Therapeutics Strengthens SAB with Leading Ataxia-Telangiectasia Expert Dr. Whitehouse - StockTitan
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts - Defense World
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Spotlight On US Penny Stocks For January 2025 - Yahoo Finance
Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World
Brokers Set Expectations for QNCX FY2024 Earnings - MarketBeat
Quince Therapeutics initiated with a Buy at Brookline - MSN
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from Analysts at Brookline Capital Management - MarketBeat
Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat
QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics regains Nasdaq compliance - Investing.com
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
Quince Therapeutics Advances Phase 3 Trial with $47.8M Cash Runway Through 2026 - StockTitan
Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
Quince Therapeutics reports positive safety data for EryDex - Investing.com India
Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK
Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53 - Business Wire
Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
US Penny Stocks To Watch In October 2024 - Yahoo Finance
Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):